Boston Scientific’s Agent DCB Granted NTAP From CMS

August 4, 2025—Boston Scientific recently announced that the US Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the company’s Agent drug-coated balloon (DCB).

Beginning October 1, 2025, CMS will provide hospitals with additional device reimbursement when the Agent DCB is used for eligible cases in the hospital inpatient setting, advised the company.

The Agent DCB received FDA approval in the United States in 2024. It is also commercially available in various international markets, noted the company.

According to Boston Scientific, the Agent device is a dedicated treatment for coronary in-stent restenosis in patients with coronary artery disease and is an alternative treatment to conventional balloon angioplasty.

The CMS NTAP was created to facilitate patient access for qualifying new medical technologies that substantially improve the diagnosis or treatment of Medicare beneficiaries, noted Boston Scientific.